OmniAb Results Presentation Deck

Our Business OUR BUSINESS MODEL IS FOCUSED ON LICENSING OUR PROPRIETARY DISCOVERY TECHNOLOGY WORLDWIDE O INDUSTRY'S ONLY 4-SPECIES PLATFORM TRANSGENIC ANIMALS FOR FULLY HUMAN AND BISPECIFIC ANTIBODY DISCOVERY LEADING AND PROVEN TECHNOLOGY 69 PARTNERS HAVE ACCESS TO OMNIAB ANTIBODIES 291 PROGRAMS WITH 3 PRODUCT APPROVALS ONE OF THE LARGEST GREENFIELDS IN THE PHARMA INDUSTRY $279 BILLION TOTAL ADDRESSABLE MARKET FOR ANTIBODIES BY 2025 WE ARE MEETING A GLOBAL INDUSTRY NEED, POISED FOR GROWTH 4 OmniAb

View entire presentation